Glider | $4,000,000 | (Apr 18, 2025)
Graze Social | $1,000,000 | (Apr 18, 2025)
Nyobolt | $30,000,000 | (Apr 18, 2025)
Certified by Founder
Lodge
Latigo Biotherapeutics, Inc.
start up
United States
- Thousand Oaks, CA
- 15/02/2024
- Series A
- $135,000,000
Latigo Biotherapeutics Inc., headquartered in Thousand Oaks, CA, is a privately held clinical-stage biotechnology company developing best-in-class non-opioid pain medicines that target the fundamental mechanism of pain transduction. The company’s proprietary, in-house technology generates novel drugs against targets validated by human genetics using the most advanced artificial intelligence, machine learning, structure-based, and knowledge-based design techniques to optimize potency and selectivity. The company is backed by top-tier investors, including Westlake Village BioPartners, 5AM Ventures, Foresite Capital, and Corner Ventures.
- Industry Biotechnology Research
- Website https://latigobio.com/
- LinkedIn https://www.linkedin.com/company/latigobio/
Booked it | $3,316,375 | (Apr 18, 2025)
FOTENIX | $2,785,755 | (Apr 18, 2025)
Exaforce Inc. | $75,000,000 | (Apr 18, 2025)
Pillar Security | $9,000,000 | (Apr 18, 2025)
Cy4Data Labs | $10,000,000 | (Apr 18, 2025)
Meadow | $14,000,000 | (Apr 18, 2025)
Trellis Health | $1,800,000 | (Apr 18, 2025)
RISA | $3,500,000 | (Apr 18, 2025)
Vizzy | B Corp™ | $4,841,908 | (Apr 18, 2025)
Assort Health | $26,000,000 | (Apr 18, 2025)